MARTINO, ENRICA ANTONIA
 Distribuzione geografica
Continente #
NA - Nord America 334
AS - Asia 131
EU - Europa 118
AF - Africa 48
SA - Sud America 31
Totale 662
Nazione #
US - Stati Uniti d'America 328
SG - Singapore 85
IT - Italia 51
IE - Irlanda 38
CI - Costa d'Avorio 33
BR - Brasile 28
CN - Cina 28
SN - Senegal 11
VN - Vietnam 7
DE - Germania 6
GB - Regno Unito 5
RU - Federazione Russa 5
CA - Canada 4
BE - Belgio 3
IN - India 3
MA - Marocco 3
CZ - Repubblica Ceca 2
GR - Grecia 2
HK - Hong Kong 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AT - Austria 1
CH - Svizzera 1
CO - Colombia 1
EC - Ecuador 1
EG - Egitto 1
FI - Finlandia 1
GL - Groenlandia 1
MX - Messico 1
PH - Filippine 1
PL - Polonia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
UA - Ucraina 1
Totale 662
Città #
Santa Clara 95
Singapore 71
Chandler 63
Chicago 42
Dublin 38
Abidjan 33
Civitanova Marche 22
Florence 13
Ashburn 12
Boardman 12
Dakar 11
Cambridge 9
Andover 8
Lawrence 8
Des Moines 4
Dong Ket 4
Wilmington 4
Beijing 3
Belo Horizonte 3
Bernareggio 3
Brussels 3
Hanoi 3
Hefei 3
Los Angeles 3
Munich 3
Athens 2
Catania 2
Hanover 2
Hong Kong 2
Kochi 2
Nanchang 2
Nanjing 2
Newham 2
Norwalk 2
Ottawa 2
Saint Petersburg 2
Seattle 2
São Paulo 2
Tianjin 2
Verona 2
Ahmetli 1
Araranguá 1
Bratislava 1
Brejo Santo 1
Brno 1
Cairo 1
Caruaru 1
Casablanca 1
Curitiba 1
Dalian 1
Dammam 1
Grafing 1
Gravatá 1
Guarujá 1
Guayaquil 1
Ibiá 1
Itabira 1
Jiaxing 1
Joinville 1
Lagoa do Itaenga 1
Las Vegas 1
Lavras 1
Manchester 1
Mandaluyong 1
Medellín 1
Mexico City 1
Miami 1
Milan 1
Monmouth Junction 1
Montes Claros 1
Montreal 1
Nanaimo 1
Natal 1
New York 1
Noida 1
Nuuk 1
Paulo Afonso 1
Perico 1
Peruíbe 1
Piraju 1
Pittsburgh 1
Praia Grande 1
Ribeirão das Neves 1
Rio das Ostras 1
Salvador 1
San Francisco 1
Santa Cruz das Palmeiras 1
São Bernardo do Campo 1
Tashkent 1
Temara 1
The Dalles 1
Torre A Mare 1
Turku 1
Valparaíso de Goiás 1
Washington 1
Totale 558
Nome #
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 78
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 77
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 69
Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report 68
Primary diffuse cutaneous plasmacytoma: when a correct clinico-pathologic approach is mandatory for the patient's health 66
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 65
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 53
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 48
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 46
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 44
Risk factors for adverse events after elective colorectal surgery: beware of blood transfusions 31
Mesenchymal Stromal Cells (MSC) As Key Players in the Tumor Microenvironment Transformation from MGUS to Myeloma 24
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 12
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands 10
Totale 691
Categoria #
all - tutte 3.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.008


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 0 0 0 0 4
2020/202124 0 0 1 3 5 0 4 0 2 0 3 6
2021/202249 1 10 1 0 8 1 10 1 3 0 2 12
2022/2023155 9 17 4 15 14 18 0 32 28 0 13 5
2023/202491 1 24 2 3 4 25 0 3 0 1 18 10
2024/2025350 13 68 25 30 64 51 20 13 18 26 22 0
Totale 691